Cardiovascular disease has significantly impacted the health and overall quality of life for a diverse spectrum of animals, spanning from household pets and domesticated animals to wildlife. In the United States, over 10 percent of canines are afflicted by cardiovascular disease, with its prevalence escalating alongside age. As a professional animal disease diagnosis company, BioVenic is steadfast in its dedication to furnishing comprehensive and precise development services for animal cardiovascular disease in vitro diagnostics.
What Is Animal Cardiovascular Disease? ▼
Animal cardiovascular disease pertains to a category of ailments that impact the heart and vascular system of animals, sharing resemblances with cardiovascular conditions in humans. Domesticated animals including dogs, cats, horses, cattle, sheep, and pigs are notably susceptible to cardiovascular diseases. Of these, dogs and cats exhibit the most severe cases. Among the prevalent animal cardiovascular disorders are Cardiomyopathy, pericarditis, valvular heart disease, arrhythmia, Hypertension, and vascular diseases, to name a few.
Animal Cardiovascular Disease Diagnostics Development Services
A comprehensive array of diagnostic techniques, including blood tests, urinalysis, electrocardiograms, blood pressure assessments, and cardiac imaging, is conventionally employed for the identification of heart disease. However, at BioVenic, our focus is on integrating cutting-edge technology, meticulous data analysis, and a multidisciplinary approach. Through the utilization of genomic analysis, proteomic profiling, and immunological methodologies like ELISA, we deliver diagnostic resolutions that embody enhanced precision and dependability. The essence of our service is encapsulated in the subsequent few key points.
Comprehensive Biomarkers Analysis
At the nucleus of our diagnostics development lies the meticulous analysis of cardiovascular disease biomarkers. These molecular signatures act as profound indicators, offering insights into the subtlest nuances of heart health. BioVenic has advanced technologies and a team of experts to help clients dissect genetic markers, scrutinize protein profiles, and evaluate physiological responses.
High-Throughput Sequencing and Profiling
Through molecular diagnostic technologies such as next-generation sequencing, we help customers deeply study the genetic code of cardiovascular diseases and discover subtle mutations in genes. This in-depth genetic analysis provides a comprehensive view of the genetic landscape, helping clients identify underlying genetic predispositions to cardiovascular disease. At the same time, we provide all reagents development such as nucleic acid probes, polymerases, and buffers involved in molecular diagnosis.
Immunodiagnostics Method Development
Immunological diagnostics methods specifically detect a large number of cardiovascular biomarkers. We provide customers with rich and diverse immunological diagnostic method development services, such as ELISA, WB, IHC, FISH, etc. In addition, we provide development services for all reagents involved in immunodiagnostics, antigens, antibodies, substrates, fluorescent markers, etc.
Optimization and Kit Development
We use extensive experience to help customers optimize different cardiovascular disease diagnostics methods from reagents, reaction conditions, targets, and other aspects. More importantly, we provide immunology- and molecular-based diagnostics kit development services. According to customers' needs, we develop microarrays targeting multiple biomarkers or design specialized and specific detection kits for single biomarkers.
Common Animal Cardiovascular Disease Biomarkers
The expedited identification and prediction of cardiovascular disease hinges upon the discernment of pertinent biomarkers. Through rigorous research undertaken by BioVenic, a spectrum of biomarkers has been pinpointed to facilitate the diagnosis of cardiovascular disease. Noteworthy among these are high-sensitivity cardiac troponins (hs-cTn), B-type natriuretic peptide (BNP), and specific microRNA profiles, which have emerged as pivotal indicators of cardiac stress, impairment, and restructuring. We provide diagnostics solutions for biomarkers including, but not limited to, the ones in the table.▼
|
Cardiovascular Disease
|
Biomarkers
|
Assay Development
|
|
Myocardial injury/myocardial infarction
|
Cardiac troponin I (cTnI), heart-type fatty acid-binding protein (h-FABP), myoglobin, creatine kinase MB (CK-MB), etc.
|
ELISA, IFA, CPIA, microarray
|
|
Blood vessel/coagulation system
|
D-Dimer, etc.
|
ELISA, IFA, CPIA, microarray
|
|
Cardiac function
|
BNP, N-terminal-pro-BNP (NT-proBNP), etc.
|
ELISA, IFA, CPIA, microarray
|
|
Brain injury markers
|
S100 protein
|
ELISA, IFA, CPIA, microarray
|
|
Cardiovascular inflammatory
|
High sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2), etc.
|
ELISA, IFA, CPIA, microarray
|
|
Ischemic heart disease
|
Serum response factor (SRF), thrombospondin 1-5 (THBS1-5), etc.
|
ELISA, IFA, CPIA, microarray
|
|
Hypertrophic cardiomyopathy
|
hs-cTn
|
ELISA, IFA, CPIA, microarray
|
|
Valvular regurgitation
|
BNP, etc.
|
ELISA, IFA, CPIA, microarray
|
|
Dilated cardiomyopathy
|
BNP、cTnI, etc.
|
ELISA, IFA, CPIA, microarray
|
Our Service Process
Why Choose Us?
Robust Reactivity
Our investigations have led us to discern pertinent biomarkers tailored to diverse animal species and varying vascular ailment classifications.
Established Verification
The diagnostic methodologies pioneered by BioVenic invariably undergo rigorous validation procedures, ensuring the utmost reliability of outcomes.
Comprehensive Methodology
Our strategy is underscored by a comprehensive multidisciplinary approach, seamlessly amalgamating the realms of genomics, proteomics, immunodiagnostics, and more.
Within the domain of animal cardiovascular disease diagnosis, BioVenic has consistently set the industry standard. We provide customers with a comprehensive and accurate one-stop animal cardiovascular disease diagnostics solution. Should you be in search of a collaborator in the realm of animal cardiovascular disease in vitro diagnostics development, we invite you to reach out to us without hesitation.
